Natalie Dakers (see below), who helped the firm move through Phase I clinical trials and raise $70 million in venture capital financing. Gallen was most recently with Wyeth Research where he held the posi
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively
in accordance with our Privacy Policy and Terms of Service.